Dr. Miriam Hanson Publications

Selected Publications

  • Hanson M, Petronic-Rosic V. Reticulated Phototoxic Eruption in a Patient on Long-term Diltiazem Therapy. J Drugs Dermatol. 2008 Aug;7:792-3.
  • Graves J, Hanson M, Cohen J. Verrucous Nodular Eruption on the Head. Arch Dermatol. 2008 Jul;144:933-8.
  • Hanson M, Hsu S. Pruritic papules on the chest and back. Am Fam Physician. 2006 Aug;74: 641-2.
  • Hill A, Hanson M, Bogle MA, Duvic M. Severe radiation dermatitis is related to Staphylococcus aureus. Am J Clin Oncol. 2004 Aug;27:361-3.
  • Hanson M, Hill A, Duvic M. Bexarotene reverses alopecia in cutaneous T-cell lymphoma. Br J Dermatol. 2003 Jul;149:193-6.
  • Hanson M, Lupski J, Hicks J, Metry D. Association of dermal melanocytosis with lysosomal storage disease: clinical features and hypotheses regarding pathogenesis. Arch Dermatol. 2003 Jul;139:916-20.

Abstracts and Poster Presentations

  • Hanson M, Metry D, Jung P, Levy M. “Association of dermal melanocytosis with lysosomal storage disease.”
    Society for Pediatric Dermatology; Annapolis, MD, Summer 2002.
  • Hanson M. “High Levels of expression of p27, p21, and cyclin E in invasive primary melanoma.”
    Baylor College of Medicine Young Investigator Assembly; Houston, TX, Summer 2001.

Clinical Trials

In accordance with the confidentiality agreement of these trials, the names of the sponsors or the drugs being investigated cannot be disclosed at this time.

  • 2007 (Co-I)

    “Multicenter randomized placebo-controlled 10-week trial comparing the efficacy of [trial drug name] to generic [drug] to vehicle (1:1:1) in patients with moderate to severe rosacea.”

  • 2007 (Co-I)

    “Multicenter randomized placebo-controlled 12-week trial comparing the efficacy of photodynamic therapy using 2 dosing regimens of [trial drug name] to vehicle (1:1:1) in patients with moderate to severe acne vulgaris.”

  • 2007 (Co-I)

    “Multicenter randomized placebo-controlled 12-week trial comparing the efficacy of [trial drug name] to vehicle (1:1) in patients with moderate to severe acne vulgaris.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 12-week trial comparing the efficacy of 2 dosing regimens of [trial drug name] to vehicle (1:1:1) in patients with moderate to severe nodulocystic acne vulgaris.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 12-week trial comparing the efficacy of 3 dosing regimens of [trial drug name] to vehicle (1:1:1:1) in patients with moderate to severe inflammatory acne vulgaris.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 2-week trial comparing the efficacy of [trial drug name] to generic [drug] to vehicle (1:1:1) in adults with moderate to severe atopic dermatitis.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 4-week trial comparing the efficacy of [trial drug name] to generic [drug] to vehicle (1:1:1) in children eight years and older with moderate to severe atopic dermatitis.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 14-week trial comparing the efficacy of 2 dosing regimens of [trial drug name] to vehicle (1:1:1) in patients with moderate to severe actinic damage.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 24-week trial comparing the efficacy of [trial drug name] to generic [drug] to vehicle (2:2:1) in patients with moderate to severe actinic damage.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 24-week trial comparing the efficacy of [trial drug name] to generic [drug] to vehicle (2:2:1) in patients with moderate to severe actinic damage.”

  • 2008 (Co-I)

    “Multicenter randomized open-label 12-week trial evaluating the efficacy of [trial drug name] in patients with moderate to severe psoriasis.”

  • 2008 (Co-I)

    “Multicenter randomized open-label 8-week trial evaluating the efficacy of [trial drug name] in patients with moderate to severe acne vulgaris.”

  • 2008 (Co-I)

    “Multicenter randomized placebo-controlled 8-week trial comparing the efficacy of 3 dosing regimens of [trial drug name] to vehicle (1:1:1:1) in patients with moderate to severe actinic damage.”

Specials
Book Online

Latest Specials & Promotions

View All